CClinicalTrials.gg
Status unknownNCT05829148Updated Apr 25, 2023

The Effect of Dexmedetomidine, Melatonin and Pregabalin

An Early Phase 1 interventional study of Dexmedetomidine and Melatonin in Endoscopic Sinus Surgery, sponsored by Egymedicalpedia. Status unknown at 1 site in Egypt. Open to participants aged 21 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-04-25.

Sponsored by Egymedicalpedia · Early Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Early Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

Various drugs have been used for the purpose: nitroglycerine, sodium nitroprusside, propofol, beta blockers, calcium channel blockers, higher concentrations of inhalational anesthetics etc. Since all these drugs have certain limitations there was a search for more safe and effective drug

Read the detailed description

Functional Endoscopic Sinus Surgery (FESS) is done via endoscope and the area is highly vascular thus it becomes important to minimize bleeding, hence we require hypotensive anesthesia.

Dexmedetomidine (a highly selective α2-receptor agonist that has sedative, analgesic, anxiolytic, and opioid sparing effects without significant respiratory depression) it also reduces the need for inhaled anesthetics. dexmedetomidine also minimizes postoperative opioid consumption as well as nausea, vomiting, and anxiety.

Melatonin is a neurohormone mainly secreted from the pineal gland by the suprachiasmatic nucleus. It possesses a circadian secretion pattern and regulates the biological clock; it also offers antiemetic, analgesic, and anxiolytic effects. Due to its effect on both acute and chronic pain, melatonin (available in 5mg tablet form) fulfills a beneficial role in reducing postoperative opioid consumption while minimizing nausea and vomiting.

Pregabalin, whose structure is similar to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), possesses analgesic and anxiolytic activities and is effective in alleviating the neuropathic component of acute nociceptive pain of surgery. It has also been used as premedication to attenuate the hemodynamic stress response to laryngoscopy and intubation and to decrease intraoperative anesthetic requirement

02

Conditions studied

  • Endoscopic Sinus Surgery
03

In context

Lead sponsor

Egymedicalpedia is the lead sponsor of 53 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients undergoing Functional endoscopic sinus surgery (ASA I \& II)

Exclusion criteria

Exclusion Criteria:

  • Hepatic, renal, endocrinal, hematological disorders.
  • BMI>30 kg/m2.
  • Patients receiving magnesium supplementation, anticonvulsant drugs or antipsychotic drugs.
  • Chronic use of opioids.
  • Current treatment with β-blocker or calcium channel blocker.
  • Known allergies to any of study drugs.
  • Patients refusal to the study
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine Group

    This Group about 30 patients will receive dexmedetomidine loading dose 1 µg/kg over a period of 15 minutes and maintenance 0.2µg/kg/h throughout the surgery .

    Drug: Dexmedetomidine

  • Active comparator
    Melatonin Group

    This Group about 30 patients will receive 10 mg melatonin (2 tablets) one hour before starting of the operation.

    Drug: Melatonin

  • Active comparator
    Pregabalin Group

    This Group about 30 patients will receive oral pregabalin 150 mg one hour before starting of the operation..

    Drug: Pregabalin

  • Placebo comparator
    Control Group

    This Group about 30 patients will receive oral starch tablet as a control. Heart rate (HR) and blood pressure values will be recorded at various intervals.

    Drug: Placebo

Interventions

  • DrugDexmedetomidine

    Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus

  • DrugMelatonin

    Melatonin

  • DrugPregabalin

    Pregabalin

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Pain Relieve

    Assessment of the pain post-operatively in patients with pain score by VAS as : Total scores vary from 0 to 10 in this method, with a higher score indicating more severe pain,

    Time frame: 2 hours post operative

Secondary outcomes

  1. controlled pulse rate

    Hemodynamics stability

    Time frame: From base line to 1 hour after the end of the operation

  2. controlled blood pressure

    Hemodynamics stability

    Time frame: From base line to 1 hour after the end of the operation

07

Study locations

1 site
  • Al-Azhar University hospitals
    Cairo, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05829148
Lead sponsor
Egymedicalpedia
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
May 1, 2023 (estimated)
Primary completion
Nov 1, 2024 (estimated)
Completion
Nov 20, 2024 (estimated)
Last update
Apr 25, 2023

Study contacts

Tarek Mounir, Professor
Contact
tarekmunir99@gmail.com
+201012140880
Mohamed AbdelGawad, Assist.Prof
study chair · Al-Azhar University, Faculty of medicine for boys

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion